http://orcid.org/0000-0002-6682-4630
Figures
Abstract
Background
The natriuretic peptide hormones play an important role in salt and blood pressure regulation. In observational studies, obesity and insulin resistance have been consistently associated with lower concentrations of natriuretic peptides. It has been proposed that insulin influences natriuretic peptide production.
Objective
We sought to determine the acute effects of insulin administration on natriuretic peptide concentrations.
Methods
31 men and women (11 lean, 10 overweight, and 10 obese), ages 30–70 years, without cardiovascular disease or overt diabetes underwent a hyperinsulinemic-euglycemic insulin clamp. Plasma concentrations of N-terminal pro atrial natriuretic peptide (NT-proANP) and N-terminal pro B-type natriuretic peptide (NT-proBNP) were measured at baseline and steady-state (the final 30 minutes of the clamp protocol).
Results
From baseline to steady-state, insulin levels increased from a mean level of 9.5 to 176.7 μU/ml (p<0.001). Over this period, circulating NT-proANP concentrations decreased by 9% (-1933 ng/L, p = 0.01). The changes in NT-proANP did not differ between lean, overweight, and obese individuals. Steady-state NT-proANP levels, adjusted for baseline, were lower in individuals with greater insulin resistance, independent of BMI. In contrast to NT-proANP, NT-proBNP levels did not change significantly during the clamp (p = 0.41).
Conclusion
Insulin administration was associated with a moderate decrease in circulating NT-proANP, but not NT-proBNP. The lowest NT-proANP concentrations were found in insulin-resistant individuals. Further investigations are warranted to elucidate potential mechanisms underlying the effects of insulin on the cardiac hormonal axis.
Citation: Bachmann KN, Deger SM, Alsouqi A, Huang S, Xu M, Ferguson JF, et al. (2018) Acute effects of insulin on circulating natriuretic peptide levels in humans. PLoS ONE 13(5): e0196869. https://doi.org/10.1371/journal.pone.0196869
Editor: Claudio Passino, Ospedale del Cuore G Pasquinucci Fondazione Toscana Gabriele Monasterio di Massa, ITALY
Received: December 5, 2017; Accepted: April 21, 2018; Published: May 14, 2018
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Data Availability: All files are available from the Open Science Framework database (https://osf.io/9fxb5/).
Funding: Research reported in this publication was supported by the American Heart Association awards (https://research.americanheart.org) 14SFRN20770008 (S.M.D., T.A.I.) and 15SDG24890015 (J.F.F.); the National Institutes of Health (https://www.nih.gov) Clinical Translational Science Award UL1TR000445 (T.A.I.) from the National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases awards T32DK007061 (K.N.B.), P30 DK020593 (K.D.N.), K24 DK62849 (T.A.I.), and Vanderbilt O’Brien Mouse Kidney Center Grant P30 DK079341 (T.A.I.); National Heart, Lung, and Blood Institute award R01 HL102780 (T.J.W.); Vanderbilt University Medical Center Faculty Research Scholars award (http://my.vanderbilt.edu/vfrs) (K.N.B.), and U.S. Department of Veterans Affairs (https://www.research.va.gov/funding/) under Award Number 1I01CX000414 (T.A.I.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The cardiac natriuretic peptide (NP) hormonal system plays an important role in salt balance, blood pressure regulation, and cardiovascular homeostasis. Natriuretic peptides appear to protect against the development of hypertension and cardiovascular risk [1–3]. In addition, emerging evidence suggests that the NP system may play a protective role in metabolism [4–7].
Large cohort studies have demonstrated that obese individuals have lower circulating levels of both atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), compared with lean individuals [8, 9]. The low NP levels in obese individuals appear to reflect a relative “NP deficiency.” Given the protective role of the NPs, a relative NP deficiency in obesity may contribute to the greater risk of cardiometabolic disease in obese individuals.
The mechanisms underlying the low NP levels in obesity are not well-understood. Proposed explanations include increased clearance of NPs in adipose tissue in obese subjects, secretion of bioactive substances by adipose tissue that affect NP production in the heart, alterations in sex hormone production and activity, and insulin resistance [10]. Regarding the latter hypothesis, some evidence suggests that insulin resistance contributes to lower NP levels, above and beyond adiposity [9]. Thus, NP levels in individuals who are lean but insulin-resistant are nearly as low as those in obese, insulin-resistant individuals [9]. These observations raise the possibility that insulin itself may influence NP production, but data from human studies are mixed [11–21]. The hyperinsulinemic-euglycemic insulin clamp is a useful technique that permits the effects of insulin to be examined, independent of excursions in glucose. Thus, we performed a physiologic study using this technique to examine the acute effects of high-dose insulin administration on circulating NP levels.
Materials and methods
Subjects
This study included 31 men and women: 11 lean (BMI < 25 kg/m2), 10 overweight (25 ≤ BMI < 30 kg/m2), and 10 obese (BMI ≥ 30 kg/m2). Subjects were between 30 and 70 years of age (mean age, 50 years) and had a history of pre-hypertension, as defined by systolic blood pressure 120–139 mmHg and/or diastolic blood pressure 80–89 mmHg. Subjects with a history of pre-hypertension were recruited because this study was part of a larger study focused on the development of hypertension among individuals with pre-hypertension. All study procedures in the present report were performed at the baseline visit prior to any intervention. Exclusion criteria were cardiovascular events within the prior 6 months, impaired renal function (estimated glomerular filtration rate < 45 ml/min/1.73m2), impaired hepatic function (aspartate amino transaminase and/or alanine amino transaminase > 1.5 times the upper limit of normal range), diabetes mellitus requiring medical therapy, morbid obesity (BMI > 45 kg/m2), current use of anti-hypertensive medication or glucocorticoids, and pregnancy. Cardiovascular history was assessed by conducting a thorough history from the individual at the screening visit. None of the subjects in the present report had experienced an acute cardiovascular event in the prior 6 months, nor had a history of coronary artery disease, myocardial infarction, congestive heart failure, pacemaker/defibrillator, peripheral vascular disease, or abnormalities on cardiovascular physical exam. We did not perform formal echocardiographic studies to exclude cardiac disease in these subjects. A complete metabolic panel and a urine sample were collected to rule out kidney and hepatic dysfunction. The Institutional Review Board at Vanderbilt University Medical Center approved the study protocol, and written informed consent was obtained from all subjects.
Study design
Study procedures were performed at the General Clinical Research Center at Vanderbilt University Medical Center. Data included in the present report were collected during 11/2014–1/2016. After fasting overnight for at least 8 hours, subjects underwent a hyperinsulinemic-euglycemic insulin clamp protocol, using a primed continuous intravenous infusion of human insulin at the rate of 2 mU/kg/min throughout the clamp protocol. Plasma glucose concentration was measured at the bedside every 5 minutes, and an infusion of 20% dextrose was titrated to maintain the basal blood glucose level. After steady-state conditions were achieved (target glucose maintained with a constant dextrose infusion rate), the clamp was continued for a final 30 minutes. The final 30 minutes of the clamp were considered the steady-state period. The duration of the clamp protocols ranged from approximately 100–150 minutes, depending on the time required to achieve steady-state conditions. The total body glucose disposal rate (GDR, mg/kg/min) was determined using the glucose infusion rate during the steady-state period, and served as a measure of in vivo insulin sensitivity.
Hormone measurements
Plasma N-terminal pro atrial natriuretic peptide (NT-proANP) (1–98) concentration was measured using a sandwich ELISA assay (Biomedica, Vienna, Austria). All samples in the present study were run in duplicate, with an average CV of < 7%. Plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) concentration was measured using an electrochemiluminescence immunoassay (Roche Elecsys ProBNP II, Roche Diagnostics, Indianapolis, IN). Details of this method have been reported previously [22]. The intra-assay CV is ≤ 1.2% at the Vanderbilt research laboratory. NP levels were measured at baseline, and at the beginning and end of the 30-minute steady-state period. The “steady-state” value refers to the mean of the values at the beginning and end of steady-state.
Plasma insulin concentration was determined by radioimmunoassay using a double antibody procedure (MilliporeSigma, Billerica, Massachusetts). The inter-assay and intra-assay CVs are 9.9% and 2.9%, respectively, at the Vanderbilt research laboratory that tested the samples in the present study. Plasma glucose concentration was measured by the glucose oxidase method (Analox GM9 glucose analyser; Analox Instruments, Stourbridge, United Kingdom).
Blood samples were drawn into tubes containing EDTA (K3) 0.10 mL 15% solution tube (Covidien) and were placed on ice immediately. Within 10 minutes on average, the samples were centrifuged at 3000 rpm for 15 minutes. They were transferred to aliquot tubes, and stored at -80°C until testing in batches at Vanderbilt research laboratories. No freeze-thaw cycles occurred prior to testing. Samples were stored at -80°C for ≤16 months. <24 months, and ≤15 months before testing for NT-proANP, NT-proBNP, and insulin levels, respectively.
Statistical analysis
Baseline characteristics were reported as median (lower quartile, upper quartile) for continuous variables and as percentages for categorical variables. Descriptive statistics at baseline were compared between the 3 BMI categories (lean, overweight, and obese) using the Kruskal-Wallis test for continuous variables and the Pearson Chi-square test for categorical variables. Insulin and natriuretic peptide concentrations (Fig 1) were reported in box plots displaying the median, interquartile range, and upper and lower adjacent values.
(Panel A) Insulin levels increased from baseline to steady-state (mean increase of 167 μU/ml, p<0.001) in the group as a whole. (Panel B) NT-proANP in the group as a whole decreased from baseline to steady-state (mean decrease of 1933 ng/L, p = 0.01), representing a 9% relative decrease. (Panel C) NT-proBNP did not change significantly from baseline to steady-state in the group as a whole (mean change -0.45 ng/L, p = 0.40).
Baseline and steady-state NP levels were compared using the paired Wilcoxon signed rank test. Next, we examined which factors impacted the changes in NP levels using multivariable regression. Changes in NP levels were analyzed using multivariable linear regression, with steady-state NP level as the response variable, and with baseline NP level as an independent variable (e.g. “steady-state NP adjusted for baseline”), which is equivalent to NP changes. In order to examine which factors impacted the changes in NP levels, we included pre-specified predictors, including BMI, age, sex, race (white vs. non-white), and glucose disposal rate, as independent variables in the regression. Two-sided p-values <0.05 were considered statistically significant. R version 3.3.1 (R foundation of Statistical Computing, Vienna, Austria) was used for statistical analyses.
Results
Baseline characteristics of the subjects, stratified by BMI category are displayed in Table 1. Baseline insulin levels were slightly higher in obese individuals compared with lean and overweight individuals, but the magnitude of the differences was small. Glucose levels did not differ at baseline. Glucose disposal rate during steady-state (a measure of insulin sensitivity) was significantly lower in obese individuals compared with lean (p = 0.02) and overweight (p = 0.02) individuals.
Circulating baseline and steady-state (the mean of the values at the beginning and end of steady-state) concentrations of insulin, NT-proANP, and NT-proBNP are shown in Fig 1A, 1B and 1C, respectively. As expected, insulin levels increased (from a mean level of 9.5 μU/ml to 176.7 μU/ml, p<0.001) during the hyperinsulinemic-euglycemic clamp (Fig 1A).
Circulating NT-proANP levels decreased from baseline to the mean of steady-state levels (mean decrease of 1933 ng/L, 95% confidence interval [557–3309], p = 0.01), representing a 9% relative decrease, in the group as a whole (Fig 1B). The magnitude of changes in NT-proANP levels did not differ according to BMI category (p = 0.38) or continuous BMI (p = 0.68). In contrast to NT-proANP, circulating NT-proBNP levels did not change significantly from baseline to steady-state in the group as a whole (mean change -0.45 ng/L, p = 0.40) (Fig 1C). Results were very similar when analyzing changes from baseline to the beginning of steady-state, and from baseline to the end of steady-state (S1 Fig). Furthermore, results were similar in secondary analyses restricted to women.
Steady-state NT-proANP levels were positively associated with glucose disposal rate (R = 0.42, p = 0.02) (Fig 2). Moreover, changes in NT-proANP levels (steady-state adjusted for baseline) were positively associated with glucose disposal rate, both in unadjusted models (partial R = 0.50, p = 0.005) and after adjustment for BMI, age, sex, and race (partial R = 0.49, p = 0.01). A lower glucose disposal rate by 1 mg/kg/min was associated with a lower steady-state NT-proANP level by 456 ng/L, after adjustment for baseline NT-proANP, BMI, age, sex, and race. We also tested interaction terms between BMI subgroup and glucose disposal rate and found that the interactions were not significant (p = 0.29 for NT-proANP by BMI subgroup, and p = 0.74 for NT-proBNP by BMI subgroup). In addition, the results were very similar after additional adjustment for the amount of fluid administered during the clamp and for outpatient dietary salt intake.
Steady-state NT-proANP levels were positively associated with glucose disposal rate (a measure of insulin sensitivity). This relationship persisted after adjustment for baseline NT-proANP levels, BMI, age, sex, and race.
Discussion
In this study of healthy individuals across a wide range of BMIs, we demonstrate that acute exposure to supraphysiologic insulin concentrations led to a modest reduction in circulating NT-proANP levels. Furthermore, lower insulin sensitivity, independent of BMI, was associated with lower NT-proANP concentrations at steady-state during hyperinsulinemic-euglycemic clamp. These observations suggest that insulin action may contribute to the differences in NT-proANP observed in obese compared with lean individuals. The findings underscore the importance of understanding mechanisms by which hyperinsulinemia and/or insulin resistance influence the cardiac hormonal axis.
Our results are consistent with some prior insulin clamp studies [13–15, 18] but not others [11, 12, 16, 17, 19–21]. Pivovarova et al. conducted one of the larger prior studies, in which 25 overweight individuals underwent a hyperinsulinemic-euglycemic clamp and experienced a decrease in circulating midregional-proANP (MR-proANP) levels [13]. In a separate study, the same group found that MR-proANP levels decreased in 14 obese men who underwent hyperinsulinemic clamps [13]. Our study extends these results to a group of individuals across a wider range of BMIs. However, not all prior clamp studies have found a decrease in NP levels in response to insulin [11, 12, 16, 17, 19–21]. The present study addresses some of the limitations of prior studies. First, most prior studies focused on a narrower range of BMIs, making it difficult to know whether observed NP changes were modified by obesity status. Second, most prior insulin clamp studies measured the mature ANP peptide, which is very sensitive to volume status and salt exposure, and undergoes rapid degradation in plasma. Third, very few prior clamp studies measured BNP or BNP propeptides. In the present study, we analyzed the propeptides of both ANP and BNP, which are more stable than the mature peptides. We used improved assays and adjusted for many possible confounders of NP (including outpatient dietary salt intake and the volume received during the infusions). Finally, we reported changes in NP levels from baseline to “steady-state,” defined as the mean NP level at the beginning and end of steady-state, in order to capture the effects on NP levels during the entire steady-state period.
Whether the decreases in NT-proANP in the present study occurred because of decreases in production, or increases in clearance, of NPs is unknown. Exposure of insulin-sensitive mice cardiomyocytes to insulin may stimulate increased BNP expression [23], an effect that may be mediated by phosphatidylinositol 3-kinase-AKT (PI3K-AKT) signaling. The apparent discordance with the human findings could be attributable to differences in NP physiology between rodents and humans, differences in timescale, involvement of NP clearance mechanisms, or activation of alternate intracellular insulin signaling pathways. For instance, insulin administration does appear to stimulate increased expression of the NP clearance receptor in adipose tissue [13], though this is expected to principally influence clearance of mature ANP and BNP, rather than their propeptides. Little is known about the mechanisms by which circulating NP propeptides are cleared. In addition, the differences between the in vitro rodent study and the current human study could be related to differential pathway-specific insulin sensitivity. The actions of insulin at the cellular level are complex and involve diverse signaling pathways, including the PI3K-AKT and Mitogen-Activated Protein Kinase (MAPK) pathways [24, 25]. The increase in NP expression in murine cardiomyocytes after exposure to insulin appears to be mediated by the PI3K-AKT pathway [23]. It is possible that insulin affects the NP system via the MAPK pathway [26]. Evidence also exists in other tissues that the PI3K and MAPK pathways can differentially regulate the effects of insulin action [24]. This raises the possibility that the observed decrease in proANP in the human study could potentially reflect the net effect of actions mediated by multiple pathways.
Interestingly, steady-state ANP levels, adjusted for baseline, were lower in individuals with poorer insulin sensitivity, independent of BMI. Thus, although the NT-proANP levels decreased in the group as a whole, individuals who were very sensitive to insulin experienced smaller decreases, or even increases, in NT-proANP levels. These findings are consistent with observations in large cohort studies that patients with insulin resistance (as assessed by HOMA-IR) have lower NP levels independent of BMI [9]. Our study confirms this relationship in a well-characterized group of patients whose insulin sensitivity was measured using the gold standard (glucose disposal rate during a hyperinsulinemic-euglycemic clamp). This study supports the concept that insulin resistance plays a role in the relative “NP deficiency” in obesity. The etiology of NP deficiency in obesity is likely multifactorial and may result from the interactions of several physiologic and pathological factors [10], including insulin resistance, alterations in sex steroids which can affect both body fat distribution and the NP system [10, 27–29], and complex interactions between adipose tissue and cardiac endocrine function [10, 30–40]. Prior studies have supported that substances secreted by adipose tissue, including pro-inflammatory adipokines and some cytokines, may affect NP gene transcription [10, 30–38], and additionally, that NPs play a role in the adipose tissue function and development [10, 39, 40]. These findings suggest that complex interrelationships exist between adipose tissue and the NP system [10] and may play a role in the apparent NP deficiency in obesity. In addition, Obokata recently reported that among obese patients with heart failure with preserved ejection fraction, increased epicardial fat can induce a pericardial restraint that may reduce cardiac wall stress and thus inhibit NP production [41], contributing to a relative NP deficiency in obesity.
In contrast to NT-proANP, NT-proBNP concentrations did not change in response to insulin administration. Consistent with our findings, two prior hyperinsulinemic-euglycemic clamp studies in selected populations did not show an association between insulin infusion and changes in concentrations of BNP or NT-proBNP [13, 20]. We extend these findings to a larger sample of relatively healthy individuals across the BMI spectrum. Differences in the turnover rates between NT-proANP and NT-proBNP may have contributed to the discrepant findings between these two peptides. We measured the propeptides of ANP and BNP because they are more stable in the circulation than the active peptides [42, 43]. However, changes in concentrations of the propeptides may be harder to detect during an acute study, due to the longer half-lives. Furthermore, peptides related to the ANP system have shorter half-lives than peptides related to the BNP system [43]. Thus, it may have been easier to demonstrate the acute effects of insulin with NT-proANP than with NT-proBNP. On the other hand, it is also possible that certain factors may regulate these peptides differentially. We have previously reported that glucose may induce expression of microRNA-425, which regulates production of proANP but not proBNP [44].
Our findings may not apply to chronic changes in NP in response to interventions that impact insulin action or sensitivity. Although NT-proBNP did not change acutely in the present study in response to high-dose insulin administration, changes in NT-proBNP were positively associated with improvements in insulin sensitivity after preventive measures for Type 2 diabetes in the Diabetes Prevention Program, independent of changes in BMI and waist circumference [45].
Moreover, individuals with Type 2 diabetes randomized to pioglitazone experienced improvements in insulin sensitivity in conjunction with increases in NP bioactivity, as determined by the expression of NP receptors in adipose tissue [46]. A challenge of prior studies investigating the chronic effects of insulin sensitivity on NP levels is that interventions that affect insulin sensitivity also often affect glucose levels. Some prior studies suggest that glucose levels may independently affect NP levels [44]. Thus, the hyperinsulinemic-euglycemic clamp technique used in the present study offers the advantage of examining the effects of insulin on NP levels, independent of changes in glucose.
A limitation of the present study is the imbalance in sample size between men and women. Large population studies indicate that circulating NP concentrations are lower in men than women [29, 42, 43]. To address this limitation, we adjusted for sex in multivariable analyses, and also performed analyses in women alone, and found that the major results were unchanged. Similarly, in large population studies, circulating NP levels are significantly lower in obese compared with lean individuals [8, 9, 42]. In the present study, NP levels did not differ significantly between lean, overweight, and obese individuals at baseline, a result that is almost certainly due to chance given the relatively small sample size in each subgroup. Finally, another limitation is that we did not perform routine echocardiography in study participants. Thus, we cannot exclude the possibility that some participants, particularly those with obesity, may have had subclinical diastolic dysfunction.
In conclusion, acute exposure to high-dose insulin led to moderate decreases in circulating NT-proANP, with lower concentrations among more insulin-resistant individuals. Further studies are warranted to elucidate potential mechanisms underlying the effects of insulin on NT-proANP production, and on the chronic effects of insulin on the cardiac hormonal axis.
Supporting information
S1 Fig. Changes in circulating NP concentrations from baseline to the beginning and end of steady-state during hyperinsulinemic-euglycemic clamp.
NT-proANP in the group as a whole decreased significantly from baseline to the beginning of steady-state (mean decrease of 1979 ng/L, 95% confidence interval [656–3304], p = 0.005; Panel A), and from baseline to the end of steady-state (mean decrease of 1886 ng/L, 95% confidence interval [345–3428], p = 0.03, Panel B). In contrast, NT-proBNP did not change significantly from baseline to the beginning of steady-state (Panel C), or from baseline to the end of steady-state (Panel D).
https://doi.org/10.1371/journal.pone.0196869.s001
(TIFF)
Acknowledgments
We would like to thank Dr. Jens Titze for his review and support of the manuscript, and Kelsey Tomasek for running the natriuretic peptide assays.
References
- 1. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41(3):348–53. Epub 2009/02/17. pmid:19219041.
- 2. Vasan RS, Glazer NL, Felix JF, Lieb W, Wild PS, Felix SB, et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. Jama. 2009;302(2):168–78. pmid:19584346.
- 3. Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. Journal of the American College of Cardiology. 2011;58(6):629–36. pmid:21798427.
- 4. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. JClinEndocrinolMetab. 2005;90(6):3622–8.
- 5. Birkenfeld AL, Budziarek P, Boschmann M, Moro C, Adams F, Franke G, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes. 2008;57(12):3199–204. pmid:18835931.
- 6. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122(3):1022–36. pmid:22307324.
- 7. Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab. 2012;97(2):638–45. Epub 2011/11/25. pmid:22112816.
- 8. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594–600. pmid:14769680
- 9. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96(10):3242–9. Epub 2011/08/19. pmid:21849523.
- 10. Clerico A, Giannoni A, Vittorini S, Emdin M. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012;17(1):81–96. pmid:21523383.
- 11. Ohno Y, Suzuki H, Yamakawa H, Nakamura M, Kato Y, Saruta T. Correlation of sodium-related factors with insulin sensitivity in young, lean, male offspring of hypertensive and normotensive subjects. J Hum Hypertens. 2001;15(6):393–9. pmid:11439314.
- 12. Benedini S, Fiocchi R, Battezzati A, Sereni Piceni L, Gamba A, Mammana C, et al. Atrial natriuretic peptide in diabetic and nondiabetic patients with and without heart transplantation. Transplant Proc. 2007;39(5):1580–5. pmid:17580193.
- 13. Pivovarova O, Gogebakan O, Kloting N, Sparwasser A, Weickert MO, Haddad I, et al. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab. 2012;97(5): E731–9. pmid:22419733.
- 14. Nannipieri M, Seghieri G, Catalano C, Prontera T, Baldi S, Ferrannini E. Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm Metab Res. 2002;34(5):265–70. pmid:12063641.
- 15. Trevisan R, Fioretto P, Semplicini A, Opocher G, Mantero F, Rocco S, et al. Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. Diabetes. 1990;39(3):289–98. pmid:2137801.
- 16. Clark BA, Sclater A, Epstein FH, Elahi D. Effect of glucose, insulin, and hypertonicity on atrial natriuretic peptide levels in man. Metabolism. 1993;42(2):224–8. pmid:8474320.
- 17. Stenvinkel P, Bolinder J, Alvestrand A. Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. Diabetologia. 1992;35(11):1042–8. pmid:1473613.
- 18. Endre T, Mattiasson I, Berglund G, Hulthen UL. Insulin and renal sodium retention in hypertension-prone men. Hypertension. 1994;23(3):313–9. pmid:8125556.
- 19. Kopf D, Muhlen I, Kroning G, Sendzik I, Huschke B, Lehnert H. Insulin sensitivity and sodium excretion in normotensive offspring and hypertensive patients. Metabolism. 2001;50(8):929–35. pmid:11474481.
- 20. Tanabe A, Naruse M, Wasada T, Naruse K, Yoshimoto T, Omori Y, et al. Effects of acute hyperinsulinemia on plasma atrial and brain natriuretic peptide concentrations. Eur J Endocrinol. 1995;132(6):693–8. pmid:7788008.
- 21. Zois NE, Terzic D, Faerch K, Plomgaard P, Hansen JS, Rossing P, et al. Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans. EBioMedicine. 2017;17:88–94. pmid:28262549.
- 22. Prontera C, Zucchelli GC, Vittorini S, Storti S, Emdin M, Clerico A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. Clin Chim Acta. 2009;400(1–2):70–3. Epub 2008/11/11. pmid:18992732.
- 23. Zhang H, Thoonen R, Yao V, Buys E, Popovich J, Su YR, et al. Regulation of B-type natriuretic peptide synthesis by insulin in obesity in male mice. Experimental physiology. 2015. pmid:26446173.
- 24. Rahmouni K, Morgan DA, Morgan GM, Liu X, Sigmund CD, Mark AL, et al. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J Clin Invest. 2004;114(5):652–8. pmid:15343383.
- 25. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806. pmid:11742412.
- 26. Tokudome T, Horio T, Yoshihara F, Suga S, Kawano Y, Kohno M, et al. Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. Metabolism. 2004;53(6):710–5. Epub 2004/05/28. pmid:15164316.
- 27. Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. Journal of the American College of Cardiology. 2007;49(1):109–16. pmid:17207730.
- 28. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005;112(14):2163–8. pmid:16203929.
- 29. Lam CS, Cheng S, Choong K, Larson MG, Murabito JM, Newton-Cheh C, et al. Influence of sex and hormone status on circulating natriuretic peptides. Journal of the American College of Cardiology. 2011;58(6):618–26. pmid:21798425.
- 30. Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care. 2008;31(4):758–60. pmid:18184904.
- 31. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology. 2005;42(6):1339–48. pmid:16317688.
- 32. Lappas M, Permezel M, Rice GE. Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2. Endocrinology. 2005;146(8):3334–42. pmid:15905315.
- 33. Mascareno E, Beckles D, Dhar-Mascareno M, Siddiqui MA. Enhanced hypertrophy in ob/ob mice due to an impairment in expression of atrial natriuretic peptide. Vascul Pharmacol. 2009;51(2–3):198–204. pmid:19560554.
- 34. Mattioli B, Giordani L, Quaranta MG, Viora M. Leptin exerts an anti-apoptotic effect on human dendritic cells via the PI3K-Akt signaling pathway. FEBS Lett. 2009;583(7):1102–6. pmid:19250936.
- 35. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochemical and biophysical research communications. 2005;334(4):1092–101. pmid:16039994.
- 36. Tong KM, Shieh DC, Chen CP, Tzeng CY, Wang SP, Huang KC, et al. Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and promotion of NF-kappaB/p300 binding in human synovial fibroblasts. Cell Signal. 2008;20(8):1478–88. pmid:18501560.
- 37. Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Paivarinta U, Moilanen T, et al. Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage—mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Mediators Inflamm. 2009;2009:345838. pmid:19688109.
- 38. Yuan K, Yu J, Shah A, Gao S, Kim SY, Kim SZ, et al. Leptin reduces plasma ANP level via nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol. 2010;298(4):R1007–16. pmid:20071611.
- 39. Costello-Boerrigter LC, Burnett JC Jr. A new role for the natriuretic peptides: metabolic regulators of the adipocyte. Journal of the American College of Cardiology. 2009;53(22):2078–9. pmid:19477359.
- 40. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008;19(4):130–7. pmid:18337116.
- 41. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6–19. pmid:28381470.
- 42. Clerico A, Passino C, Franzini M, Emdin M. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta. 2015;443:17–24. pmid:24937843.
- 43. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol. 2006;290(1):H17–29. pmid:16373590.
- 44. Arora P, Wu C, Hamid T, Arora G, Agha O, Allen K, et al. Acute Metabolic Influences on the Natriuretic Peptide System in Humans. Journal of the American College of Cardiology. 2016;67(7):804–12. pmid:26892417.
- 45. Walford GA, Ma Y, Christophi CA, Goldberg RB, Jarolim P, Horton E, et al. Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia. 2014;57(5):935–9. pmid:24554005.
- 46. Kovacova Z, Tharp WG, Liu D, Wei W, Xie H, Collins S, et al. Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. Obesity (Silver Spring). 2016;24(4):820–8. pmid:26887289.